Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy

Redox Biology

Volumn 2, Issue 1, 2014, Pages 289-295

  Areti, Aparna ^a   Yerra, Veera Ganesh ^a   Naidu, VGM ^a   Kumar, Ashutosh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Chemotherapy; Mitochondria; Mitotoxicity; Nutraceuticals; Oxidative stress; Peripheral neuropathy

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BORTEZOMIB; CISPLATIN; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; VINCA ALKALOID; ANTIOXIDANT; FREE RADICAL; NUTRACEUTICAL; REACTIVE OXYGEN METABOLITE; NEUROPROTECTIVE AGENT; PEROXYNITROUS ACID;

ADVERSE OUTCOME; APOPTOSIS; CANCER CHEMOTHERAPY; DISEASE ACTIVITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; INCIDENCE; MITOCHONDRION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; ADVERSE DRUG REACTION; BIOENERGY; CANCER PATIENT; CELL STRESS; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CONTROLLED CLINICAL TRIAL (TOPIC); DIET THERAPY; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; NERVE CELL LESION; NERVE INJURY; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYTONUTRIENT; PLEIOTROPY; PROSPECTIVE STUDY; TARGET CELL DESTRUCTION; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DRUG EFFECTS; METABOLISM; NERVE CELL; NERVE DEGENERATION; NEURALGIA; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; HUMANS; MITOCHONDRIA; NERVE DEGENERATION; NEURALGIA; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PERIPHERAL NERVOUS SYSTEM DISEASES; PEROXYNITROUS ACID;

EID: 84893358928     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.01.006     Document Type: Review

References (48)

1. Ferrier J., Pereira V., Busserolles J., Authier N., Balayssac D. Emerging trends in understanding chemotherapy-induced peripheral neuropathy. Current Pain and Headache Reports 2013, 17:364-371.
2. Wolf S., Barton D., Kottschade L., Grothey A., Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur. J. Cancer 2008, 44:1507-1515.
3. Wang X.-M., Lehky T.J., Brell J.M., Dorsey S.G. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012, 59:3-9.
4. Brzezinski K. Chemotherapy-induced polyneuropathy. Part I. Pathophysiology. Contemp. Oncol. (Poznań, Poland) 2012, 16:72-80.
5. Argyriou A.A., Bruna J., Marmiroli P., Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit. Rev. Oncol./Hematol. 2012, 82:51-77.
6. Conklin K.A. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr. Cancer Ther. 2004, 3:294-300.
7. Low P.A., Nickander K.K., Tritschler H.J. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997, 46:S38-S42.
8. Xiao W.H., Bennett G.J. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain 2012, 153:704-709.
9. Negi G., Kumar A., Joshi R.P., Sharma S.S. Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle. Biochem. Biophys. Res. Commun. 2011, 408:1-5.
10. Negi G., Kumar A., Sharma S.S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kB and Nrf2 cascades. J. Pineal Res. 2011, 50:124-131.
11. Prasad S.N., Muralidhara Neuroprotective effect of geraniol and curcumin in an acrylamide model of neurotoxicity in Drosophila melanogaster: relevance to neuropathy. J. Insect Physiol. 2013, 60:7-16.
12. Saifi G.M., Szigeti K., Snipes G.J., Garcia C.A., Lupski J.R. Molecular mechanisms, diagnosis, and rational approaches to management of and therapy for Charcot-Marie-Tooth disease and related peripheral neuropathies. J. Investig. Med.: Off. Publ. Am. Fed. Clin. Res. 2003, 51:261-283.
13. McDonald E.S., Windebank A.J. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol. Dis. 2002, 9:220-233.
14. Salvemini D., Little J.W., Doyle T., Neumann W.L. Roles of reactive oxygen and nitrogen species in pain. Free Radic. Biol. Med. 2011, 51:951-966.
15. Ta L.E., Schmelzer J.D., Bieber A.J., Loprinzi C.L., Sieck G.C., Brederson J.D., Low P.A., Windebank A.J. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PloS One 2013, 8:e54161.
16. Ganesh Yerra V., Negi G., Sharma S.S., Kumar A. Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-kB pathways in diabetic neuropathy. Redox Biol. 2013, 1:394-397.
17. Negi G., Kumar A., Sharma S.S Nrf2 and NF-kB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes. Curr. Neurovasc. Res. 2011, 8:294-304.
18. Lupachyk S., Shevalye H., Maksimchyk Y., Drel V.R., Obrosova I.G. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function. Free Radic. Biol. Med. 2011, 50:1400-1409.
19. Negi G., Kumar A., Sharma S.S. Concurrent targeting of nitrosative stress & PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy. Biochem. Biophys. Res. Commun. 2010, 391:102-106.
20. Janes K., Doyle T., Bryant L., Esposito E., Cuzzocrea S., Ryerse J., Bennett G.J., Salvemini D. Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. Pain 2013, 154:2432-2440.
21. Jin H.W., Flatters S.J.L., Xiao W.H., Mulhern H.L., Bennett G.J. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp. Neurol. 2008, 210:229-237.
22. Podratz J.L., Knight A.M., Ta L.E., Staff N.P., Gass J.M., Genelin K., Schlattau A., Lathroum L., Windebank A.J. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol. Dis. 2011, 41:661-668.
23. Zheng H., Xiao W.H., Bennett G.J. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp. Neurol. 2012, 238:225-234.
24. Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel-and oxaliplatin-evoked painful peripheral neuropathy. Exp. Neurol. 2011, 232:154-161.
25. Xiao W.H., Zheng H., Zheng F.Y., Nuydens R., Meert T.F., Bennett G.J. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience 2011, 199:461-469.
26. Flatters S.J.L., Bennett G.J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006, 122:245-257.
27. Melli G., Taiana M., Camozzi F., Triolo D., Podini P., Quattrini A., Taroni F., Lauria G. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp. Neurol. 2008, 214:276-284.
28. Giordano S., Darley-Usmar V., Zhang J. Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol. 2013, 2.
29. Bianchi G., Vitali G., Caraceni A., Ravaglia S., Capri G., Cundari S., Zanna C., Gianni L. Symptomatic and neurophysiological responses of paclitaxel-or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur. J. Cancer 2005, 41:1746-1750.
30. Gedlicka C., Kornek G.V., Schmid K., Scheithauer W. Amelioration of docetaxel/cisplatin induced polyneuropathy by α-lipoic acid. Ann. Oncol. 2003, 14:339-340.
31. Schloss J.M., Colosimo M., Airey C., Masci P., Linnane A.W., Vitetta L. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin. Nutr. 2013, 32:888-893.
32. Kamat C.D., Gadal S., Mhatre M., Williamson K.S., Pye Q.N., Hensley K. Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J. Alzheimers Dis. 2008, 15:473-493.
33. Cavaletti G., Frigeni B., Lanzani F., Mattavelli L., Susani E., Alberti P., Cortinovis D., Bidoli P. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur. J. Cancer 2010, 46:479-494.
34. Jaggi A.S., Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012, 291:1-9.
35. Scripture C.D., Figg W.D., Sparreboom A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr. Neuropharmacol. 2006, 4:165-172.
36. Argyriou A.A., Polychronopoulos P., Iconomou G., Chroni E., Kalofonos H.P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat. Rev. 2008, 34:368-377.
37. Jain K.K. Drug-induced peripheral neuropathies. Drug-Induced Neurological Disorders 2001, 263-294. Hogrefe & Huber. K.K. Jain (Ed.).
38. Smith R.A.J., Hartley R.C., Cocheme H.M., Murphy M.P. Mitochondrial pharmacology. Trends Pharmacol. Sci. 2012, 33:341-352.
39. Smyth J.F., Bowman A., Perren T., Wilkinson P., Prescott R.J., Quinn K.J., Tedeschi M. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann. Oncol. 1997, 8:569-573.
40. Cascinu S., Catalano V., Cordella L., Labianca R., Giordani P., Baldelli A.M., Beretta G.D., Ubiali E., Catalano G. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2002, 20:3478-3483.
41. Nahleh Z., Pruemer J., Lafollette J., Sweany S. Melatonin, a promising role in taxane-related neuropathy. Clin. Med. Insights: Oncol. 2010, 4:35-41.
42. Lin P.-C., Lee M.-Y., Wang W.-S., Yen C.-C., Chao T.-C., Hsiao L.-T., Yang M.-H., Chen P.-M., Lin K.-P., Chiou T.-J. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support. Care Cancer 2006, 14:484-487.
43. Ghoreishi Z., Esfahani A., Djazayeri A., Djalali M., Golestan B., Ayromlou H., Hashemzade S., Jafarabadi M.A., Montazeri V., Keshavarz S.A. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer 2012, 12:1-8.
44. Wang W.-S., Lin J.-K., Lin T.-C., Chen W.-S., Jiang J.-K., Wang H.-S., Chiou T.-J., Liu J.-H., Yen C.-C., Chen P.-M. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007, 12:312-319.
45. Visovsky C., Collins M., Abbott L., Aschenbrenner J., Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin. J. Oncol. Nurs. 2007, 11:901-913.
46. Kottschade L.A., Sloan J.A., Mazurczak M.A., Johnson D.B., Murphy B.P., Rowland K.M., Smith D.A., Berg A.R., Stella P.J., Loprinzi C.L. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support. Care Cancer 2011, 19:1769-1777.
47. Pace A., Savarese A., Picardo M., Maresca V., Pacetti U., Del Monte G., Biroccio A., Leonetti C., Jandolo B., Cognetti F. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J. Clin. Oncol. 2003, 21:927-931.
48. Pace A., Giannarelli D., Galia E., Savarese A., Carpano S., Della Giulia M., Pozzi A., Silvani A., Gaviani P., Scaioli V. Vitamin E neuroprotection for cisplatin neuropathy A randomized, placebo-controlled trial. Neurology 2010, 74:762-766.